More News About Calcium Antagonists
Michael H. Alderman I f this keeps up, calcium antagonists are going to get a very bad reputation. Already, in some circles, reports of adverse cardiovascular,lgastrointestinal,2 and now neoplastic3 consequences have generated a strong avoidance reaction. How justified is such a response? How solid are the data upon which the reaction is based? What is a reasonableposturefor the responsible physician? Specifically, for those whose primary interest has been hypertension,how should this new information influence our decisions? What must patients be told? Where do we go from here?
Calcium antagonistsare powerfulagentswith multiple effects. The short acting variety have long been used in the management of a variety of vascular conditions in pursuitof therapeuticas well as preventivebenefit.Much, if not all of the early justification for their use derived from a combinationof preclinicaland clinicalstudies employing surrogate endpoints.These studies appropriately focusedupon physiologicalor pathologicalfeaturesof the vascular system. In many cases, the desired effect was achieved.For example,blood pressurereductionhas been readily achieved with a minimum of side effects. Effects on symptoms and pathological expressions of vascular disease have also sometimes been quite favorable. Presumably,in view of these findings,calciumchannelblockers have achieved enormous popularity in the treatment of coronary artery disease states and, by extrapolation,in the control of high blood pressure!
WHAT SHOULD WE KNOW?
Were physicians justified in building a treatment strategy based on this kind of data? The ideal and widely accepted gold standard for determining the value of therapeutic interventions is the prospective randomized controlled trial. Calcium antagonists have generally not been subjected to such rigorous analysis. The reason, of course, for demanding this level of evidence is that although we may select drugs to accomplish a health goal because of a demonstrated effect on a single physiological parameter or pathological process, what we really care about is the overall health effect of the drug. Drugs invariably have effects that go beyond those sought or anticipated. Indeed, they frequently have wholly unanticipated consequences. Thus, a full scale prospective trial, having morbidity and mortality as endpoints, may yield results contrary to those anticipated based on surrogate endpoint studies. Antiarrhythmic agents are only one case in point.5
WHAT HAVE WE LEARNED?
Regrettably, the report from Pahor et al, in this issue of the American Journal of Hypertension,3 is but one more in a growing list of disturbing findings that bring into question the safety of immediate release calcium antagonists. Multiple bits of trial data in the treatment of coronary artery related disease has suggested that cardiovascular mortality may be increased in those treated with calcium antagonists.6 Observational data in hypertensive patients found the incidence of myocardial infarction to be increased in patients receiving calcium antagonists in comparison to other antihypertensive agents.7 Then, in a study recently published in Lancet, the suggestion has surfaced that gastrointestinal bleeding may also be a problem for calcium antagonist treated patients.2 None of these studies, by themselves, are conclusive. All involve, almost exclusively, the short acting variety of calcium antagonist. The results seen with the short acting forms cannot automatically be extrapolated to apply to the more recently introduced long acting calcium antagonists.
What then can we make of the available data? First of all, it seems reasonable to admit that the enormous popularity achieved by calcium antagonists over the ill transfer to these unproven drugs, JNC V had it " right.'~Diuretics and~-blockers first-others when necessary or specifically indicated.
8. Where do we go from here? As always, more data and less talk would be helpful. Prospective, randomized trials-particularly the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) comparing diuretics, angiotensin 9 converting enzyme inhibitors, a-blockers, and a long acting calcium antagonist-are underway .14We who treat hypertension can confidently rely on proven
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strategies, eschewing any course correction until compelling positive evidence appears. 1, 2.
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